This inventor holds 3 USPTO granted patents and 2 published patent applications. Top assignee: Oclassen Pharmaceuticals, Inc.. Active years: 1992-2000.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Suisun City, CA (US) (1992)
- Suisun, CA (US) (1995 - 2000)
Company Filing History:
Years Active: 1992-2000
Title: Dennis W. Adair: Innovator in Pharmaceutical Compositions
Introduction
Dennis W. Adair is a notable inventor based in Suisun, California. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antiviral compositions. With a total of 3 patents, his work focuses on innovative methods for treating infections caused by various viruses.
Latest Patents
Adair's latest patents include groundbreaking methods for treating infections caused by herpes virus strains resistant to acyclovir. His research has revealed that low dosage amounts of 1-(2'-deoxy-2'-fluoro-.beta.-D-arabinofuranosyl)-5-iodouracil (FIAU) can effectively inhibit the replication of acyclovir-resistant HSV strains. Additionally, he has developed methods for treating infections caused by the Hepatitis B virus (HBV). His findings indicate that administering low doses of FIAU to chronically infected individuals can drastically reduce circulating markers associated with HBV.
Career Highlights
Dennis W. Adair is associated with Oclassen Pharmaceuticals, Inc., where he continues to advance his research in antiviral therapies. His work has been instrumental in addressing the challenges posed by drug-resistant viral infections.
Collaborations
Adair has collaborated with notable colleagues, including Kenneth A. Smiles and Dannie H. King. Their combined expertise has contributed to the success of their research initiatives.
Conclusion
Dennis W. Adair's innovative work in pharmaceutical compositions showcases his commitment to improving treatment options for viral infections. His contributions are vital in the ongoing battle against drug-resistant viruses.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile